SPT Labtech, BellBrook Labs Automate Screening for VPS4B ATPase Inhibitors for Cancer Drug Discovery

Why It Matters

Automating VPS4B screening reduces reagent use and speeds hit identification, giving oncology drug programs a competitive edge, while reinforcing SPT Labtech’s role as a versatile automation partner across drug discovery and genomics markets.

Key Takeaways

• Miniaturized assay identifies 13 new VPS4B inhibitors.
• Dragonfly + Transcreener enables 384‑ and 1536‑well formats.
• Automation cuts reagent consumption while preserving high Z’ values.
• SPT expands platform upgrades and global manufacturing footprint.
• Partnerships accelerate biotech workflows in oncology and genomics.

Pulse Analysis

VPS4B ATPase has emerged as a compelling oncology target because its over‑expression in certain tumors creates a synthetic‑lethal vulnerability when paired with its paralog VPS4A. Traditional screening for ATPase inhibitors is hampered by high reagent costs and complex assay formats, limiting throughput and slowing lead generation. By integrating BellBrook Labs’ Transcreener ADP2 fluorescence‑polarization readout with SPT Labtech’s dragonfly positive‑displacement dispenser, researchers now have a fully automated, homogeneous assay that delivers consistent high Z' scores, essential for reliable hit discovery.

The combined platform’s ability to run in both 384‑ and 1536‑well plates dramatically shrinks reaction volumes, cutting reagent consumption by orders of magnitude while preserving assay sensitivity. This efficiency enabled BellBrook to identify 13 structurally diverse VPS4B inhibitors in a single campaign, a result that would have required substantially more manual effort and material under conventional workflows. The high‑precision dispensing of the dragonfly system ensures reproducible liquid handling, a critical factor when measuring subtle changes in ADP production that drive fluorescence‑polarization signals.

Beyond the immediate drug‑discovery impact, the partnership signals SPT Labtech’s strategic expansion beyond its legacy genomics automation portfolio. Recent upgrades to the mosquito and firefly platforms improve user interfaces and walk‑away capabilities, positioning SPT to capture a broader segment of the life‑science automation market. Coupled with new manufacturing capacity in China and India, the company is poised to meet rising global demand for scalable, low‑volume liquid‑handling solutions that accelerate both biotech and pharmaceutical pipelines.